• Consensus Rating: Moderate Buy
  • Consensus Price Target: $12.67
  • Forecasted Upside: -1.73%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$12.89
▲ +0.09 (0.70%)

This chart shows the closing price for ALVO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Alvotech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALVO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALVO

Analyst Price Target is $12.67
▼ -1.73% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Alvotech in the last 3 months. The average price target is $12.67, with a high forecast of $20.00 and a low forecast of $8.00. The average price target represents a -1.73% upside from the last price of $12.89.

This chart shows the closing price for ALVO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 2 contributing investment analysts is to moderate buy stock in Alvotech. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/27/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/22/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/22/2024BarclaysBoost TargetOverweight ➝ Overweight$17.00 ➝ $20.00Low
1/29/2024BarclaysUpgradeEqual Weight ➝ Overweight$10.00 ➝ $17.00Low
10/20/2023CitigroupUpgradeSell ➝ Neutral$5.00 ➝ $10.00Low
9/21/2023BarclaysInitiated CoverageEqual Weight$10.00Low
6/30/2023Deutsche Bank AktiengesellschaftLower Target$12.00 ➝ $8.00Low
3/7/2023Deutsche Bank AktiengesellschaftBoost TargetHold$8.00 ➝ $12.00Low
9/7/2022Morgan StanleyInitiated CoverageEqual Weight$10.00Low
9/6/2022CitigroupDowngradeBuy ➝ Sell$12.00 ➝ $5.00Low
7/26/2022CitigroupInitiated CoverageBuy$12.00Low
7/1/2022Deutsche Bank AktiengesellschaftInitiated CoverageHold$10.00Low
6/29/2022DNB MarketsInitiated CoverageBuy$21.00Low
(Data available from 4/19/2019 forward)

News Sentiment Rating

0.35 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/22/2023
  • 5 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/22/2023
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/21/2023
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/21/2023
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/20/2024
  • 6 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/19/2024
  • 3 very positive mentions
  • 25 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/20/2024
  • 1 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/19/2024

Current Sentiment

  • 1 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Alvotech logo
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
Read More

Today's Range

Now: $12.89
Low: $12.72
High: $12.95

50 Day Range

MA: $14.38
Low: $11.40
High: $17.27

52 Week Range

Now: $12.89
Low: $6.70
High: $18.00

Volume

90,143 shs

Average Volume

290,022 shs

Market Capitalization

$402.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.07

Frequently Asked Questions

What sell-side analysts currently cover shares of Alvotech?

The following equities research analysts have issued research reports on Alvotech in the last twelve months: Barclays PLC, Citigroup Inc., and Deutsche Bank Aktiengesellschaft.
View the latest analyst ratings for ALVO.

What is the current price target for Alvotech?

3 Wall Street analysts have set twelve-month price targets for Alvotech in the last year. Their average twelve-month price target is $12.67, suggesting a possible downside of 1.7%. Barclays PLC has the highest price target set, predicting ALVO will reach $20.00 in the next twelve months. Deutsche Bank Aktiengesellschaft has the lowest price target set, forecasting a price of $8.00 for Alvotech in the next year.
View the latest price targets for ALVO.

What is the current consensus analyst rating for Alvotech?

Alvotech currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ALVO.

What other companies compete with Alvotech?

How do I contact Alvotech's investor relations team?

Alvotech's physical mailing address is 333 SOUTH GRAND AVENUE 28TH FLOOR, LOS ANGELES CA, 90071. The company's listed phone number is 354-422-4500 and its investor relations email address is [email protected]. The official website for Alvotech is www.alvotech.com. Learn More about contacing Alvotech investor relations.